Business
Appointment of CEO of ADOR Diagnostics
Appointment of CEO of ADOR Diagnostics.
About this update from Batm Advanced Communications Ltd.
[{"type":"text","content":"\n \n \n LEI:\n 213800FLQUB9J289RU66\n \n \n 19 July 2022\n \n \n \n \n \n \n \n \n BATM Advanced Communications Limited\n \n \n (\"BATM\" or \"the Group\")\n \n \n \n \n \n Appointment of CEO of ADOR Diagnostics\n \n \n Bioscience expert appointed to lead advanced molecular diagnostics associate company\n \n \n \n \n \n BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, is pleased to announce the appointment of Dr. Eran Zahavy as CEO of ADOR Diagnostics (\"ADOR\"), the Group's associate company that is developing the NATlab rapid molecular diagnostics platform. \n \n \n \n \n \n \n Dr. Eran Zahavy has more than 20 years\n \n ' experience in\n \n leading positions in\n \n government and private\n \n bio-science organisations.\n This includes\n \n \n \n \n \n \n role\n \n s such\n \n as\n \n R&D manager for\n \n biological pathogens d\n \n iagnostic\n \n s\n and\n \n \n \n \n \n \n \n \n Head of Innovation at\n \n the\n \n Israel Institut\n \n e\n for Biologic\n \n \n \n \n al\n Research\n \n (\"I\n \n I\n \n B\n \n R\")\n \n .\n During\n \n \n \n \n \n the pandemic\n \n , at I\n \n I\n BR\n \n \n \n he\n oversaw the development of the BriLife COVID-19 vaccine in collaboration with US-based NRx Pharmaceuticals.\n \n \n Other roles have included serving as CTO at\n \n Hutchison Kinrot,\n \n the operator of a\n \n technology incubator in Israel and\n \n a seed investor\n \n in water and cleantech-related technologies\n \n ;\n \n CTO of TACount\n \n , a developer of imaging-based microbiological testing technology\n \n ;\n \n and as scientific advisor\n \n to\n \n Longliv\n \n Ventures,\n \n a strategic investor in health-tech start-ups and part of the\n CK\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Hutchison Holdings Group\n .\n \n \n \n \n \n \n For the last few years\n \n , Dr. Zahavy has\n \n served as CTO of the Group's Bio-Medical Division and as Senior Scientific Consultant to\n \n ADOR and BATM's Adaltis diagnostics subsidiary.\n During this time, he has been\n \n \n \n \n instrumental in\n \n the\n \n progress made in the Group's molecular diagnostics activities.\n \n \n \n \n \n \n \n \n \n \n Dr.\n \n Z\n ahavy holds a PhD in Chemistry & Biophysics from the Hebrew University and\n \...